CRISPR Therapeutics AG (LON:0VRQ)

CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-488.3	-366.25	-153.61	-650.18	377.66	-348.87
Depreciation & Amortization	18.66	19.26	19.84	24.17	17.95	9.18
Asset Writedown & Restructuring Costs	96.25	-	2.5	-	-	-
Stock-Based Compensation	76.37	86.57	81.03	97.95	102.39	66.02
Other Operating Activities	-30.37	-38.62	-16.55	12.47	14.11	1.86
Change in Accounts Receivable	-	175	-200	0.31	-0.16	-0.05
Change in Accounts Payable	32.62	-27.28	-20.25	5.16	37.51	25.75
Change in Unearned Revenue	-3.19	-1.95	5.79	-1.01	-0.78	1.38
Change in Other Net Operating Assets	-4.54	10.5	20.87	15.39	-9.71	6.36
Operating Cash Flow	-302.49	-142.77	-260.38	-495.74	538.97	-238.37
Capital Expenditures	-0.65	-1.9	-9.47	-37.19	-81.71	-18.36
Sale (Purchase) of Intangibles	-25	-	-2.5	-	-	-
Investment in Securities	62.48	-278.58	386.62	-221.47	-953.73	-522.81
Investing Cash Flow	36.82	-280.48	374.65	-258.66	-1,035	-541.17
Issuance of Common Stock	326.49	331.98	62.66	38.59	250.95	1,016
Financing Cash Flow	326.49	331.98	62.66	38.59	250.95	1,016
Foreign Exchange Rate Adjustments	0.01	-0.02	0.07	-0.08	-0.01	0.04
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-	-
Net Cash Flow	60.83	-91.29	177.01	-715.88	-245.52	236.66
Free Cash Flow	-303.14	-144.68	-269.85	-532.93	457.27	-256.72
Free Cash Flow Margin	-790.73%	-387.72%	-72.69%	-44484.89%	49.98%	-35705.70%
Free Cash Flow Per Share	-3.47	-1.72	-3.41	-6.86	5.69	-3.89
Levered Free Cash Flow	-206.82	-29.27	-238.97	-337.58	284.82	-112.91
Unlevered Free Cash Flow	-206.82	-29.27	-238.97	-337.58	284.82	-112.91
Change in Working Capital	24.89	156.27	-193.59	19.85	26.86	33.44

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.